Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 10:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HPV16 Positive Clear all
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck, Unresectable Head and Neck Squamous Cell Carcinoma
Interventions
Combination Treatment of PDS0101 and Pembrolizumab, Pembrolizumab Monotherapy
Combination Product · Drug
Lead sponsor
PDS Biotechnology Corp.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
28
States / cities
Phoenix, Arizona • Greenbrae, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced May 21, 2026, 10:00 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Atypical Squamous Cells of Undetermined Significance, Cervical Cancer, High-grade Squamous Intraepithelial Lesion, Low-grade Squamous Intraepithelial Lesion
Interventions
HspE7, placebo, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2013 · Synced May 21, 2026, 10:00 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma
Interventions
CUE-101
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 21, 2026, 10:00 PM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers, Sarcoma, Uveal Melanoma, NUT Carcinoma
Interventions
Tumor and HLA Profiling
Diagnostic Test
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
21
States / cities
Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced May 21, 2026, 10:00 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer, Base of Tongue Carcinoma, Tonsil Cancer
Interventions
Transcervical Oropharyngeal Ultrasound, Oral Rinse Collection, Blood Draw
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced May 21, 2026, 10:00 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Solid Tumors
Interventions
ISA 101, Nivolumab
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced May 21, 2026, 10:00 PM EDT
Active, not recruiting Early Phase 1 Interventional
View directory record Official record
Conditions
HPV16+ Squamous Cell Carcinoma
Interventions
HB-200
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced May 21, 2026, 10:00 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma
Interventions
CUE-101, KEYTRUDA®, Pembrolizumab
Drug
Lead sponsor
Cue Biopharma
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
17
States / cities
Tucson, Arizona • Palo Alto, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced May 21, 2026, 10:00 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
Interventions
Electroporation, HPV DNA Plasmids Therapeutic Vaccine VGX-3100, Laboratory Biomarker Analysis
Device · Biological · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 10:00 PM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
Interventions
ISA101b, Cemiplimab, Placebo
Biological · Drug · Other
Lead sponsor
ISA Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
10
States / cities
Duarte, California • San Diego, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced May 21, 2026, 10:00 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Cervical Cancer
Interventions
Cemiplimab, ISA101b
Drug · Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Tucson, Arizona • Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced May 21, 2026, 10:00 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Cancer of Head and Neck, Cancer of Cervix, Cancer of Anus
Interventions
DPX-E7 vaccine, Cyclophosphamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced May 21, 2026, 10:00 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
Interventions
TSC-204-A0201, TSC-204-C0702, TSC-200-A0201, TSC-204-A0201 + TSC-204-C0702, TSC-204-A0201 + TSC-200-A0201, TSC-204-C0702 + TSC-200-A0201, TSC-204-A0201 + TSC-203-A0201, TSC-204-C0702 + TSC-203-A0201, TSC-200-A0201 + TSC-203-A0201, TSC-203-A0201, TSC-204-A0101, TSC-201-B0702, TSC-204-A0201 + TSC-204-A0101, TSC-204-A0201 + TSC-201-B0702, TSC-204-C0702 + TSC-204-A0101, TSC-204-C0702 + TSC-201-B0702, TSC-200-A0201 + TSC-204-A0101, TSC-200-A0201 + TSC-201-B0702, TSC-203-A0201 + TSC-204-A0101, TSC-203-A0201 + TSC-201-B0702, TSC-202-A0201, TSC-204-A0201 + TSC-202-A0201, TSC-204-C0702 + TSC-202-A0201, TSC-200-A0201 + TSC-202-A0201, TSC-203-A0201 + TSC-202-A0201, TSC-204-A0101 + TSC-202-A0201, TSC-201-B0702 + TSC-202-A0201
Biological
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
21
States / cities
Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced May 21, 2026, 10:00 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Oropharyngeal Cancer
Interventions
Toripalimab, Carboplatin, Paclitaxel
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced May 21, 2026, 10:00 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Vaginal Cancer, Cervical Cancer, Anal Cancer, Penile Cancer, Oropharyngeal Cancer
Interventions
Fludarabine, Cyclophosphamide, E6 TCR, Aldesleukin
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced May 21, 2026, 10:00 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer, HPV-Related Carcinoma
Interventions
MEDI0457, Durvalumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced May 21, 2026, 10:00 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Oropharyngeal Cancer
Interventions
Utomilumab, ISA101b
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced May 21, 2026, 10:00 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
HPV-Related Squamous Cell Carcinoma
Interventions
HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
Drug
Lead sponsor
Hookipa Biotech GmbH
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
26
States / cities
Birmingham, Alabama • Gilbert, Arizona • Fayetteville, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced May 21, 2026, 10:00 PM EDT
Terminated Early Phase 1 Interventional
View directory record Official record
Conditions
HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer
Interventions
HB-201 IV
Drug
Lead sponsor
Hookipa Biotech GmbH
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced May 21, 2026, 10:00 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck
Interventions
Pembrolizumab (KEYTRUDA®) and PDS0101
Combination Product
Lead sponsor
PDS Biotechnology Corp.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
18
States / cities
Greenbrae, California • San Francisco, California • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced May 21, 2026, 10:00 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, New Diagnosis Tumor, Locally Advanced
Interventions
CUE-101, Pembrolizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 21, 2026, 10:00 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Melanoma, Cervical Cancer
Interventions
RPTR-168
Biological
Lead sponsor
Repertoire Immune Medicines
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Scottsdale, Arizona • Los Angeles, California • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced May 21, 2026, 10:00 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharyngeal Cancer, Laryngeal Cancer, Sinonasal Squamous Cell Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma, Skull Base Tumors, HPV 16 Positive Oropharyngeal Tumors (OPC)
Interventions
Toripalimab + Chemotherapy, Toripalimab, Chemoradiotherapy or radiation
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced May 21, 2026, 10:00 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography, FDG-Positron Emission Tomography, Biospecimen Collection, Biopsy
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced May 21, 2026, 10:00 PM EDT